.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06B_Immunoglobulins.J06BC03_Bezlotoxumab.Bezlotoxumab .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06B_Immunoglobulins.J06BC03_Bezlotoxumab.Bezlotoxumab| name: | Bezlotoxumab | |
| ATC code: | J06BC03 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 1000 | mg |
| volume of distribution: | 7.33 | L |
| clearance: | 0.317 | L/day |
| other parameters in model implementation | ||
Bezlotoxumab is a human monoclonal antibody that binds to Clostridioides difficile toxin B and is indicated for the prevention of recurrent C. difficile infection in adults at high risk. It is administered as a single intravenous infusion and is currently approved and used in clinical practice.
Pharmacokinetic parameters in adult patients with C. difficile infection, primarily males and females aged 18–100 years, without significant hepatic or renal impairment.